Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116220 · ClinicalTrials.gov registry record · Phase 3
Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
A Phase 3 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
NCT00116220: Completed Phase 3 study, sponsored by Dana-Farber Cancer Institute.
NCT00116220 is a Phase 3 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 206 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116220, a Phase 3 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
Study Summary
This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.
Interventions
- RADIATION External Beam Radiotherapy
- DRUG Flutamide (Eulexin) and Lupron or Zoladex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 1995-09 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
What the finished NCT00116220 record still lists
NCT00116220 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which External Beam Radiotherapy is the first listed.
NCT00116220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00116220 about?
NCT00116220 is a clinical study titled "Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer". This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.
What is the current status of trial NCT00116220?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 1995-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00116220?
The interventions under investigation include: External Beam Radiotherapy (RADIATION), Flutamide (Eulexin) and Lupron or Zoladex (DRUG).
Who is sponsoring clinical trial NCT00116220?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00116220's enrollment target sits among peer trials
206 1347th of 2000 higher than 651 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia